Autoinjectors Market Size, Share, Forecast, & Trends Analysis by Type, Technology, Application, Distribution, Route of Administration, End User

Description

List of Tables

Autoinjectors Market Size, Share, Forecast, & Trends Analysis by Type (Disposable, Reusable, Wearable), Technology (Manual, Automatic), Application (Arthritis, Diabetes, Osteoporosis), Distribution, Route of Administration, End User-Global Forecast to 2031

The global autoinjectors market is projected to reach $3.76 billion by 2031 at a CAGR of 8.3% from 2024 to 2031.

Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. The growth of the increasing prevalence of chronic & autoimmune diseases, growing demand for self-administration, and technological advancements in autoinjectors. However, the availability of alternatives to autoinjectors, needlestick injury concerns, and the high costs of autoinjectors restrain the growth of this market.

Furthermore, the growing demand for home healthcare and partnerships & collaborations by market players are expected to generate growth opportunities for the players operating in this market. However, limited access to healthcare in developing countries and lack of knowledge and awareness regarding autoinjector usage in emerging economies are major challenges impacting market growth.

The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over four years (2021-2024). The key players operating in the global autoinjectors market are Becton, Dickinson and Company (U.S.), Ypsomed AG (Switzerland), SHL Medical (Switzerland), Recipharm AB (Sweden), Owen Mumford Limited (U.K), Halozyme, Inc. (U.S.), AstraZeneca (U.K.), Teva Pharmaceutical Industries Ltd. (Israel), Solteam Incorporation Co., Ltd. (China), Gerresheimer AG (Germany), West Pharmaceutical Services, Inc. (U.S.), Bayer AG (Germany), and Union Medico ApS. (Denmark).

Among all the types studied in this report, the smart autoinjectors segment is projected to register the highest CAGR of over 9.7% during the forecast period of 2024-2031. The growth of this segment is driven by technological advancements in autoinjectors and the benefits of smart autoinjectors, such as dosage accuracy through prefilled medication, reduced anxiety due to minimal needle injuries, and improved patient compliance and medication adherence.

Among all the routes of administration studied in this report, in 2024, the subcutaneous segment is expected to account for the largest share of the autoinjectors market. The segment's large market share is attributed to the availability of several drugs that are administered subcutaneously and the increasing number of new drugs being launched for subcutaneous self-administration.

Among all the technologies studied in this report, in 2024, the manual autoinjectors segment is expected to account for the largest share of the autoinjectors market. The large market share of this segment can be attributed to the increasing adoption of manual autoinjectors due to their lower prices compared to automatic autoinjectors and the easy availability of manual autoinjectors at retail pharmacies.

Among all the applications studied in this report, in 2024, the diabetes segment is expected to account for the largest share of the autoinjectors market. The large market share of this segment can be attributed to the increasing awareness programs focusing on diabetes and the high prevalence of diabetes worldwide.

Among all the distribution channels studied in this report, in 2024, the diabetes segment is expected to account for the largest share of the autoinjectors market. The large market share of this segment can be attributed to the availability of a diverse selection of autoinjectors at retail pharmacies, which enables patients to choose the most suitable autoinjector based on their specific preferences, needs, and healthcare expert recommendations.

Among all the end users studied in this report, in 2024, the home care segment is expected to account for the largest share of over 57.6% of the autoinjectors market. The large market share of this segment can be attributed to the increasing adoption of home care devices due to their convenience, precision, and accuracy. Additionally, market players have increased their focus on raising awareness about diseases such as diabetes and rheumatoid arthritis, driving the adoption of autoinjectors in home care settings.

An in-depth analysis of the geographical scenario of the global autoinjectors market provides detailed qualitative and quantitative insights into the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2024, North America is expected to account for the largest share of over 36.5% of the autoinjectors market. In the region in 2024, the U.S. is expected to account for the largest share of the autoinjectors market in North America. The large share of this regional market is attributed to the increasing incidence of diabetes, technological advancements in autoinjectors, the presence of major autoinjector manufacturers, and increasing awareness programs focusing on diabetes management in the region.

Scope of the Report:

Autoinjectors Market Assessment-by Type

Disposable Autoinjectors
Reusable Autoinjectors
Smart Autoinjectors
- Bluetooth Connectivity
- Near Field Communication (NFC) Connectivity
Wearable Autoinjectors

Autoinjectors Market Assessment-by Route of Administration

Subcutaneous
Intramuscular

Autoinjectors Market Assessment-by Technology

Manual
Automatic

Autoinjectors Market Assessment-by Application

Rheumatoid Arthritis
Osteoporosis
Diabetes
Multiple Sclerosis
Other Applications

Note: Other applications include epilepsy, oncology, anaphylaxis, migraine, and anemia.

Autoinjectors Market Assessment-by Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online/E-commerce Platforms

Autoinjectors Market Assessment-by End User

Home Care
Hospitals & Clinics
Other End Users

Note: Other end users include long-term care settings and military & defense.

Autoinjectors Market Assessment-by Geography

North America
- U.S.
- Canada
Europe
- Germany
- France
- U.K
- Italy
- Spain
- Austria
- Netherlands
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa

Product Code: MRHC - 1041216

1. Introduction

1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency & Limitations
1.4. Key Stakeholders

2. Research Methodology

2.1. Research Approach
2.2. Data Collection & Validation Process
- 2.2.1. Secondary Research
- 2.2.2. Primary Research/Interviews with Key Opinion Leaders from the Industry
2.3. Market Sizing & Forecasting
- 2.3.1. Market Size Estimation Approach
- 2.3.2. Growth Forecast Approach
- 2.3.3. Market Share Analysis
2.4. Assumptions for the Study

3. Executive Summary

4. Market Insights

4.1. Overview
4.2. Drivers
- 4.2.1. Increasing Prevalence of Chronic & Autoimmune Diseases
- 4.2.2. Growing Demand for Self-administration
- 4.2.3. Technological Advancements in Autoinjectors
4.3. Restraints
- 4.3.1. Availability of Alternatives to Autoinjectors
- 4.3.2. High Costs of Autoinjectors
- 4.3.3. Needlestick Injury Concerns
4.4. Opportunities
- 4.4.1. Growing Demand for Home Healthcare
- 4.4.2. Partnerships & Collaborations by Market Players
4.5. Challenges
- 4.5.1. Limited Access to Healthcare in Developing Countries
- 4.5.2. Lack of Knowledge and Awareness Regarding Autoinjector Usage in Emerging Economies
4.6. Trends
- 4.6.1. Smart/Electronic Autoinjectors
- 4.6.2. Increasing Adoption of Wearable Devices
4.7. Factor Analysis
4.8. Regulatory Analysis
- 4.8.1. U.S.
- 4.8.2. Canada
- 4.8.3. Europe
- 4.8.4. China
- 4.8.5. Japan
- 4.8.6. India
- 4.8.7. Latin America
- 4.8.8. Middle East
4.9. Pricing Analysis
4.10. Parent/Adjacent Market Analysis
4.11. Porter's Five Forces Analysis

5. Autoinjectors Market Assessment-by Type

5.1. Overview
5.2. Disposable Autoinjectors
5.3. Reusable Autoinjectors
5.4. Smart Autoinjectors
- 5.4.1. Bluetooth Connectivity
- 5.4.2. Near Field Communication (NFC) Connectivity
5.5. Wearable Autoinjectors

6. Autoinjectors Market Assessment-by Route of Administration

6.1. Overview
6.2. Subcutaneous
6.3. Intramuscular

7. Autoinjectors Market Assessment-by Technology

7.1. Overview
7.2. Manual
7.3. Automatic

8. Autoinjectors Market Assessment-by Application

8.1. Overview
8.2. Rheumatoid Arthritis
8.3. Osteoporosis
8.4. Diabetes
8.5. Multiple Sclerosis
8.6. Other Applications

9. Autoinjectors Market Assessment-by Distribution Channel

9.1. Overview
9.2. Hospital Pharmacies
9.3. Retail Pharmacies
9.4. Online/E-commerce Platforms

10. Autoinjectors Market Assessment-by End User

10.1. Overview
10.2. Home Care
10.3. Hospitals & Clinics
10.4. Other End Users

11. Autoinjectors Market Assessment-by Geography

11.1. Overview
11.2. North America
- 11.2.1. U.S.
- 11.2.2. Canada
11.3. Europe
- 11.3.1. Germany
- 11.3.2. France
- 11.3.3. U.K.
- 11.3.4. Italy
- 11.3.5. Spain
- 11.3.6. Austria
- 11.3.7. Netherlands
- 11.3.8. Rest of Europe
11.4. Asia-Pacific
- 11.4.1. Japan
- 11.4.2. China
- 11.4.3. India
- 11.4.4. Australia
- 11.4.5. South Korea
- 11.4.6. Rest of Asia-Pacific
11.5. Latin America
- 11.5.1. Brazil
- 11.5.2. Mexico
- 11.5.3. Rest of Latin America
11.6. Middle East & Africa

12. Competition Analysis

12.1. Overview
12.2. Key Growth Strategies
12.3. Competitive Benchmarking
12.4. Competitive Dashboard
- 12.4.1. Industry Leaders
- 12.4.2. Market Differentiators
- 12.4.3. Vanguards
- 12.4.4. Emerging Companies
12.5. Market Share Analysis/Market Rankings of Key Players (2023)

13. Company Profiles (Business Overview, Financial Overview, Product Portfolio, Strategic Developments, and SWOT Analysis*)

13.1. Novo Nordisk A/S
13.2. Eli Lilly and Company
13.3. Sanofi S.A.
13.4. Biocon Limited
13.5. Becton, Dickinson and Company
13.6. Ypsomed AG
13.7. Owen Mumford Limited
13.8. Medtronic plc
13.9. Emperra GmbH E-Health Technologies
13.10. pendiq GmbH
13.11. Jiangsu Delfu medical device Co., Ltd

(Note: SWOT analysis will be provided for the top 5 companies.)

14. Appendix

14.1. Available Customization
14.2. Related Reports